Cargando…

Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece

PURPOSE: To conduct an economic evaluation comparing Ferinject(®) (ferric carboxymaltose [FCM]) with Venofer(®) (iron sucrose [IS]) and CosmoFer(®) (low-molecular-weight iron dextran [LMWID]) in the management of iron deficiency anemia in Greece. PATIENTS AND METHODS: A cost-minimization analysis wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoulakis, Vassilis, Kourlaba, Georgia, Goumenos, Dimitris, Konstantoulakis, Manousos, Maniadakis, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358814/
https://www.ncbi.nlm.nih.gov/pubmed/22629113
http://dx.doi.org/10.2147/CEOR.S30514
_version_ 1782233808983031808
author Fragoulakis, Vassilis
Kourlaba, Georgia
Goumenos, Dimitris
Konstantoulakis, Manousos
Maniadakis, Nikolaos
author_facet Fragoulakis, Vassilis
Kourlaba, Georgia
Goumenos, Dimitris
Konstantoulakis, Manousos
Maniadakis, Nikolaos
author_sort Fragoulakis, Vassilis
collection PubMed
description PURPOSE: To conduct an economic evaluation comparing Ferinject(®) (ferric carboxymaltose [FCM]) with Venofer(®) (iron sucrose [IS]) and CosmoFer(®) (low-molecular-weight iron dextran [LMWID]) in the management of iron deficiency anemia in Greece. PATIENTS AND METHODS: A cost-minimization analysis was conducted since there are no clear data indicating that one of these regimens is superior to the others in terms of efficacy. Main data inputs were based on bibliography and validated by clinicians. The economic evaluation was conducted for inpatients (ie, surgical patients or patients hospitalized due to a disease related to chronic or acute blood loss) and outpatients (eg, nondialysis chronic kidney disease patients), separately. Analysis was carried out from a National Health Service (NHS) perspective and also from a patient perspective. Total cost treatment reflects the cost of drugs, the cost of all resources expended in patient management such as the cost of disposables for each infusion, the monitoring costs during infusion (salaries of personnel), other hospital expenses, the cost for management of adverse events, the productivity loss, and the traveling cost for patients. RESULTS: In the case of outpatients, the mean total cost per patient in the FCM arm was €198.6, in the IS arm €627.7, and in the LMWID arm, €510.5. For inpatients the mean total cost was estimated at €189.2 for FCM while it was €419.9 and €228.8 for IS and LMWID, respectively. Budget impact analysis for a typical Greek hospital with 100 patients revealed that the total cost of FCM (inpatients analysis) was 113% and 15.4% lower against their comparators. In an outpatient situation, the total cost of FCM was 201.1% and 151.8% lower compared with IS and LMWID, respectively. CONCLUSION: Ferric carboxymaltose may represent a cost-saving option compared with the most likely alternative existing therapies used for the management of anemia in the National Health Service of Greece.
format Online
Article
Text
id pubmed-3358814
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33588142012-05-24 Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece Fragoulakis, Vassilis Kourlaba, Georgia Goumenos, Dimitris Konstantoulakis, Manousos Maniadakis, Nikolaos Clinicoecon Outcomes Res Original Research PURPOSE: To conduct an economic evaluation comparing Ferinject(®) (ferric carboxymaltose [FCM]) with Venofer(®) (iron sucrose [IS]) and CosmoFer(®) (low-molecular-weight iron dextran [LMWID]) in the management of iron deficiency anemia in Greece. PATIENTS AND METHODS: A cost-minimization analysis was conducted since there are no clear data indicating that one of these regimens is superior to the others in terms of efficacy. Main data inputs were based on bibliography and validated by clinicians. The economic evaluation was conducted for inpatients (ie, surgical patients or patients hospitalized due to a disease related to chronic or acute blood loss) and outpatients (eg, nondialysis chronic kidney disease patients), separately. Analysis was carried out from a National Health Service (NHS) perspective and also from a patient perspective. Total cost treatment reflects the cost of drugs, the cost of all resources expended in patient management such as the cost of disposables for each infusion, the monitoring costs during infusion (salaries of personnel), other hospital expenses, the cost for management of adverse events, the productivity loss, and the traveling cost for patients. RESULTS: In the case of outpatients, the mean total cost per patient in the FCM arm was €198.6, in the IS arm €627.7, and in the LMWID arm, €510.5. For inpatients the mean total cost was estimated at €189.2 for FCM while it was €419.9 and €228.8 for IS and LMWID, respectively. Budget impact analysis for a typical Greek hospital with 100 patients revealed that the total cost of FCM (inpatients analysis) was 113% and 15.4% lower against their comparators. In an outpatient situation, the total cost of FCM was 201.1% and 151.8% lower compared with IS and LMWID, respectively. CONCLUSION: Ferric carboxymaltose may represent a cost-saving option compared with the most likely alternative existing therapies used for the management of anemia in the National Health Service of Greece. Dove Medical Press 2012-05-04 /pmc/articles/PMC3358814/ /pubmed/22629113 http://dx.doi.org/10.2147/CEOR.S30514 Text en © 2012 Fragoulakis et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Fragoulakis, Vassilis
Kourlaba, Georgia
Goumenos, Dimitris
Konstantoulakis, Manousos
Maniadakis, Nikolaos
Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
title Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
title_full Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
title_fullStr Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
title_full_unstemmed Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
title_short Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
title_sort economic evaluation of intravenous iron treatments in the management of anemia patients in greece
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358814/
https://www.ncbi.nlm.nih.gov/pubmed/22629113
http://dx.doi.org/10.2147/CEOR.S30514
work_keys_str_mv AT fragoulakisvassilis economicevaluationofintravenousirontreatmentsinthemanagementofanemiapatientsingreece
AT kourlabageorgia economicevaluationofintravenousirontreatmentsinthemanagementofanemiapatientsingreece
AT goumenosdimitris economicevaluationofintravenousirontreatmentsinthemanagementofanemiapatientsingreece
AT konstantoulakismanousos economicevaluationofintravenousirontreatmentsinthemanagementofanemiapatientsingreece
AT maniadakisnikolaos economicevaluationofintravenousirontreatmentsinthemanagementofanemiapatientsingreece